BD Plays It Safe
It's not often that a company gets the chance to, in effect, reinvent a major product category. Moreover, it's not often that government legislators and regulators give the company a significant boost in its effort. But that's exactly what's happened for sharps product leader Becton Dickinson & Co. As concerns about health care worker safety mount, legislation recently enacted in California requires hospitals to convert from severly price-squeezed conventional sharps products to new, specially-designed products--a kind of decommoditization of these highly commoditized product categories. And BD officials hope the California law is only the beginning.
You may also be interested in...
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.